Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ: EXEL )

33.82 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis
Via Business Wire
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months. 
Via The Motley Fool
Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the... 
Via Benzinga
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Where Exelixis Stands With Analysts
Via Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
These two companies make a compelling case for a high price. 
Via The Motley Fool
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time. 
Via InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
Analyst Expectations for Exelixis's Future
Via Benzinga
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
2 Biotech Growth Stocks I'd Buy Right Now
Both drugmakers seem to have a bright future ahead. 
Via The Motley Fool
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today. 
Via InvestorPlace
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in game-changing businesses. 
Via The Motley Fool
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
From Farallon Capital Management L.L.C.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These companies can take investors on a lucrative ride, and all for the price of a few lattes. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.